Cooley LLP advised Immatics on the deal. Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced its license, development...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here